ACB $6.530 (-5.22%)

ACNNF $0.112 (0%)

AERO $3.135 (-3.83%)

AGEEF $0.063 (-3.09%)

ALEAF $0.389 (-0.23%)

AMMJ $0.073 (-2.28%)

APHA $4.680 (0.43%)

ARNA $71.250 (0.95%)

ATT:CNX $0.080 (0%)

ATTBF $0.007 (2.33%)

AUSA:CNX $0.155 (6.9%)

AUSAF $0.123 (0%)

AVXL $4.250 (1.43%)

BAMM:CNX $0.390 (2.63%)

BBM:CNX $0.055 (10%)

BBRRF $0.040 (4.58%)

BE:CNX $0.005 (0%)

BIO:CNX $0.070 (16.67%)

BLEVF $0.004 (26.67%)

BLIS:CNX $0.315 (0%)

BLO:CNX $0.430 (-8.51%)

BLOZF $0.330 (-5.71%)

BUDZ $0.200 (-4.76%)

BXNG $0.440 (0%)

CADMF $0.633 (-4.99%)

CALI:CNX $0.070 (0%)

CANN $0.318 (5.83%)

CARA $14.530 (-1.62%)

CBII:CNX $0.190 (2.7%)

CBIIF $0.144 (1.74%)

CBWTF $0.110 (-6.38%)

CGC $16.360 (-0.24%)

CGRW $0.084 (9.09%)

CHOO:CNX $0.090 (-5.26%)

CHOOF $0.067 (-5.91%)

CNBX $0.175 (1.72%)

CNGGF $0.270 (0%)

CODI $17.700 (0.45%)

CPMD $0.650 (1.58%)

CRBP $1.900 (-3.06%)

CRON $5.290 (0.95%)

CROP:CNX $0.015 (0%)

CRTPF $2.300 (-9.95%)

CRXPF $0.050 (46.55%)

CSI:CNX $0.920 (0%)

CURR $1.440 (-3.36%)

CVSI $0.530 (3.33%)

DIGP $0.026 (1.37%)

DXBRF $0.140 (0%)

EAPH $0.001 (0%)

EAT:CNX $0.015 (50%)

EEVVF $0.054 (2.45%)

EMHTF $0.151 (-5.63%)

EPWCF $0.034 (-4.72%)

EVIO $0.017 (12.67%)

FFRMF $0.025 (0.2%)

FFT:CNX $0.040 (0%)

FNNZF $0.053 (0%)

GGTTF $0.060 (-17.15%)

GLDFF $0.017 (-4.55%)

GLH:CNX $0.020 (0%)

GNBT $0.247 (5.11%)

GRIN:CNX $0.110 (4.76%)

GRWG $15.970 (1.62%)

GSTR:CNX $0.050 (-9.09%)

GTBIF $14.100 (-0.35%)

GTII:CNX $18.620 (-0.05%)

GWPH $100.180 (-1.79%)

HEXO $0.774 (1.78%)

HLSPY $0.385 (0%)

HMLSF $4.655 (-1.58%)

HMPPF $0.498 (0%)

HRVOF $0.050 (-10.07%)

HSTRF $0.084 (5.41%)

HUGE:CNX $3.640 (-2.93%)

IAN:CNX $0.090 (0%)

IGC $1.190 (0%)

IGXT $0.150 (-1.24%)

IIPR $124.790 (-1.1%)

IMLFF $3.678 (-1.14%)

INQD $0.003 (0%)

IONC:CNX $0.015 (0%)

IONKF $0.015 (-28.57%)

ISOL:CNX $0.035 (16.67%)

ISOLF $0.030 (34.53%)

ITHUF $0.072 (-5.3%)

IVITF $0.007 (84.21%)

JWCAF $0.004 (0%)

KBEV:CNX $0.060 (0%)

KBEVF $0.041 (-7.22%)

KHRNF $0.359 (-2.93%)

KSHB $0.470 (1.73%)

LHS:CNX $0.510 (-1.92%)

LHSIF $0.396 (0.76%)

LOVE:CNX $0.090 (0%)

LXRP $0.265 (-2.48%)

LXX:CNX $0.345 (-1.43%)

MCIG $0.028 (0%)

MEDIF $0.676 (-2.55%)

MGWFF $0.051 (-9.94%)

MICWF $0.079 (0%)

MJ:CNX $0.035 (0%)

MJNA $0.014 (0.36%)

MNTR $0.080 (-2.38%)

MRRCF $0.004 (5.88%)

MWM:CNX $0.095 (0%)

MYM:CNX $0.055 (-8.33%)

MYMMF $0.041 (-12.21%)

NCNNF $0.140 (6.87%)

NDVAF $0.186 (-5.11%)

NGW:CNX $0.215 (-2.27%)

NRXCF $0.093 (-8.79%)

NSPDF $0.049 (-3.07%)

NTEC $0.283 (0.86%)

NVTQF $0.451 (0%)

NWKRF $0.424 (0%)

NXGWF $0.165 (-0.93%)

NXTTF $0.187 (-0.21%)

OH:CNX $5.330 (0%)

ORHOF $4.050 (0%)

OWCP $0.009 (-0.56%)

PHCG $0.500 (0%)

PHVAF $0.038 (-5.71%)

PILL:CNX $0.650 (0%)

PKG:CNX $0.075 (-6.25%)

PLPRF $0.460 (-2.56%)

PLUS:CNX $0.610 (-1.61%)

PMCB $0.011 (-7.89%)

PNPL $0.200 (0%)

POTN $0.014 (5.19%)

PRCNF $0.008 (-15.79%)

PTNYF $0.055 (-3.74%)

QCA:CNX $0.125 (4.17%)

RDDTF $0.082 (-11.54%)

RLLVF $0.041 (-30.51%)

RMHB $0.053 (1.92%)

RQB:CNX $0.005 (0%)

RQHTF $0.181 (1.68%)

RVVQF $0.007 (-12.5%)

SLNG:CNX $0.135 (3.85%)

SMG $149.130 (-3.63%)

SNN:CNX $0.155 (0%)

SNNVF $0.115 (15%)

SOL:CNX $1.050 (2.94%)

SOLCF $0.747 (-1.76%)

SPLIF $0.012 (14.5%)

SPRWF $0.115 (-3.69%)

SRNA $0.023 (-0.44%)

STEM:CNX $0.340 (11.48%)

STMH $0.260 (8.33%)

SUN:CNX $0.150 (-14.29%)

TBPMF $0.131 (0%)

TCAN:CNX $0.930 (-1.06%)

TCNAF $0.708 (0%)

TER:CNX $6.000 (0%)

TGEN $0.752 (-4.86%)

TGIF:CNX $0.060 (0%)

TGIFF $0.045 (-3.62%)

THC:CNX $0.140 (-3.45%)

THCBF $0.106 (-3.64%)

TLRY $5.340 (-1.66%)

TOKI:CNX $0.030 (0%)

TRLFF $0.027 (8%)

TRSSF $4.530 (-0.22%)

TRTC $0.073 (2.16%)

TURV $0.117 (-10.28%)

VBIO $0.160 (-20%)

VIDA:CNX $0.055 (0%)

VIN:CNX $0.015 (0%)

VPRB $0.023 (4.55%)

VRNDF $0.443 (0%)

VRT:CNX $0.150 (0%)

VRTHF $0.115 (0%)

VVCIF $0.152 (0.76%)

WAYL:CNX $0.740 (0%)

WDDMF $0.243 (-7.72%)

WLDFF $0.120 (0.5%)

XXII $0.570 (-2.11%)

ZDPY $0.225 (-6.25%)

ZYNE $3.700 (-2.63%)

Technical420 Site Search

Returned 15 result(s).

GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors

GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board of Directors. Mr. Gryska will also serve as a member of the Audit Committee. Mr. Gryska brings valuable global pharmaceutical and biotechnology…

3 Cannabis Price Target Upgrades Investors Need To Know

Earnings season has started to heat up and US cannabis companies have been in focus. In this article, we are not referring to multi-state operators (MSOs) but companies like GW Pharmaceuticals (GWPH), Innovative Industrial Properties, Inc. (IIPR), and the Scotts Miracle-Gro Company (SMG). In regards to GW, IIPR and Scotts,…

FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex

GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., today announced the U.S. Food and Drug Administration (FDA) has approved EPIDIOLEX® (cannabidiol) oral solution to treat seizures associated with tuberous sclerosis complex (TSC)…

3 CBD Companies To Watch In A Post Covid-19 World

COVID-19 is expected to have a long-lasting impact on how consumers spend money and this is a trend that our readers need to be aware of. Over the next year, we believe that the average consumer will become far more cost conscious and this trend should have a significant impact…

Cardiol Therapeutics To Benefit On The Rescheduling Of GW Pharma’s Epidiolex By The DEA

Earlier this year, the Drug Enforcement Administration (DEA) announced a significant development for patients who need to access Epidiolex, the only federally approved drug derived from cannabis. Epidiolex is manufactured and sold by GW Pharmaceuticals (GWPH) and is no longer considered to be a controlled substance under the Controlled Substances…

GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA) for Cannabidiol for the Treatment of Tuberous Sclerosis

GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS).…

GW Pharmaceuticals Announces Up To $258.75 Million In Underwritten Deals

GW Pharmaceuticals plc (Nasdaq:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to market and other conditions, $225 million of American Depositary Shares (“ADSs”) representing ordinary shares of GW on the NASDAQ Global…

Why is GW Pharma Down 15% this Morning?!?

GW Pharmaceuticals (GWPH) is under heavy pressure and the shares are down more than 15% this morning.This drop is not based off data and it is not based off anything cannabis related. This plunge comes after GW’s competition reported significantly better data for its Dravet syndrome product.A GW Competitor Reports Much…

GW Pharmaceuticals Receives Another Favorable Upgrade

GW Pharmaceuticals (GWPH) is the bellwether of the biotech cannabis sector and we are favorable on the firm heading into the back half of 2017.GW is changing the landscape of the biotech industry. The company already sells a cannabis-derived treatment for multiple sclerosis in 27 countries and it has by…

Betting on Biotech: Has GW Pharma Found a Bottom?

The biotech sector will be one of the greatest beneficiaries of the legal cannabis movements and we continue to view this as one of the most attractive opportunities for investors.The opportunity to invest in a high-growth industry in the first inning of a multi-decade growth cycle does not come around…

Older Posts »

Search Again